Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Kieron Dunleavy, M.D., National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00007345
First received: December 16, 2000
Last updated: March 25, 2016
Last verified: March 2016
Results First Received: January 14, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Cutaneous T Cell Lymphoma
Peripheral T Cell Lymphoma
Intervention: Drug: Romidepsin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Although 7 cohorts were written in the protocol, the cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.

Reporting Groups
  Description
Peripheral T-cell Lymphoma (PTCL) Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
Cutaneous T-cell Lymphoma (CTCL) Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.

Participant Flow:   Overall Study
    Peripheral T-cell Lymphoma (PTCL)     Cutaneous T-cell Lymphoma (CTCL)  
STARTED     47     84  
COMPLETED     45     73  
NOT COMPLETED     2     11  
Refused further treatment                 0                 7  
Switched to alternative treatment                 0                 3  
Intercurrent illness                 1                 0  
Death on study                 1                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Although 7 cohorts were written in the protocol, the cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.

Reporting Groups
  Description
Peripheral T-cell Lymphoma (PTCL) Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
Cutaneous T-cell Lymphoma (CTCL) Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
Total Total of all reporting groups

Baseline Measures
    Peripheral T-cell Lymphoma (PTCL)     Cutaneous T-cell Lymphoma (CTCL)     Total  
Number of Participants  
[units: participants]
  47     84     131  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     31     57     88  
>=65 years     16     27     43  
Age  
[units: years]
Mean (Standard Deviation)
  58.97  (12.56)     57.85  (13.08)     58.25  (12.86)  
Gender  
[units: participants]
     
Female     22     27     49  
Male     25     57     82  
Ethnicity (NIH/OMB)  
[units: participants]
     
Hispanic or Latino     1     4     5  
Not Hispanic or Latino     46     80     126  
Unknown or Not Reported     0     0     0  
Race (NIH/OMB)  
[units: participants]
     
American Indian or Alaska Native     0     0     0  
Asian     3     0     3  
Native Hawaiian or Other Pacific Islander     0     0     0  
Black or African American     4     17     21  
White     40     65     105  
More than one race     0     0     0  
Unknown or Not Reported     0     2     2  
Region of Enrollment  
[units: participants]
     
United States     39     55     94  
Australia     8     29     37  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With a Response   [ Time Frame: up to 56.5 days ]

2.  Primary:   Duration of Response (DOR)   [ Time Frame: up to 127 months ]

3.  Secondary:   Number of Participants With Adverse Events   [ Time Frame: 147 months and 5 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
7 cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Kieron Dunleavy
Organization: National Cancer Institute
phone: 301-435-1007
e-mail: DunleavK@mail.nih.gov


Publications of Results:
Other Publications:


Responsible Party: Kieron Dunleavy, M.D., National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00007345     History of Changes
Obsolete Identifiers: NCT00020436
Other Study ID Numbers: 010049
01-C-0049
Study First Received: December 16, 2000
Results First Received: January 14, 2016
Last Updated: March 25, 2016
Health Authority: United States: Federal Government
United States: Food and Drug Administration